Cargando…
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantif...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717685/ https://www.ncbi.nlm.nih.gov/pubmed/36467062 http://dx.doi.org/10.3389/fphar.2022.1045235 |
_version_ | 1784842940527411200 |
---|---|
author | Wang, Dongmei Liu, Jieying Zhong, Ling Li, Shunhua Zhou, Liyuan Zhang, Qian Li, Ming Xiao, Xinhua |
author_facet | Wang, Dongmei Liu, Jieying Zhong, Ling Li, Shunhua Zhou, Liyuan Zhang, Qian Li, Ming Xiao, Xinhua |
author_sort | Wang, Dongmei |
collection | PubMed |
description | Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantify the effects of SGLT2 inhibitors on biomarkers of inflammation in randomized controlled trials (RCTs). Methods: PubMed, Cochrane Library, EMBASE, and Web of Science were searched for eligible RCTs of adults with type 2 diabetes (T2D) with no time limit (updated to 12 October 2022). The biomarkers selected included C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, leptin, adiponectin, ferritin, plasminogen activator inhibitor (PAI)-1, and vascular cell adhesion molecule-1. Data were analyzed using a random-effect model in Review Manager 5.4. Results: Thirty-four studies with 6,261 patients (68.6% male) were eligible for this meta-analysis. The mean age of the participants was 62.57(±11.13) years old, and the median treatment duration length with follow-up was 24 weeks. Generally, the included trials were of good methodological quality. The meta-analysis revealed that ferritin levels were significantly reduced in SGLT2 inhibitor treatment groups versus placebo or standard diabetes therapies (SMD: −1.21; 95% CI: −1.91, −0.52, p < 0.001). The effects of CRP (SMD: 0.25; 95% CI: −0.47, −0.03, p = 0.02) and leptin (SMD: −0.22; 95% CI: −0.43, −0.01, p = 0.04) were reduced, and the effects of adiponectin were improved (SMD: 0.28; 95% CI: 0.15, 0.41, p < 0.001) in placebo-controlled studies. PAI-1 levels were significantly reduced in studies controlled for diabetes therapies (SMD: −0.38; 95% CI: −0.61, −0.15, p = 0.001). Conclusion: This analysis provides strong evidence supporting anti-inflammatory effects of SGLT2 inhibitors in T2D subjects. The mechanisms and possible targets for the inflammation reducing and cardiorenal protective properties of SGLT2 inhibitors remain to be explored. |
format | Online Article Text |
id | pubmed-9717685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97176852022-12-03 The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials Wang, Dongmei Liu, Jieying Zhong, Ling Li, Shunhua Zhou, Liyuan Zhang, Qian Li, Ming Xiao, Xinhua Front Pharmacol Pharmacology Aims: Inflammatory biomarkers may play vital roles in the pathophysiology of diabetes and diabetic cardiorenal complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a potential cardiovascular and renal protective effect in type 2 diabetes. The aim of this meta-analysis was to quantify the effects of SGLT2 inhibitors on biomarkers of inflammation in randomized controlled trials (RCTs). Methods: PubMed, Cochrane Library, EMBASE, and Web of Science were searched for eligible RCTs of adults with type 2 diabetes (T2D) with no time limit (updated to 12 October 2022). The biomarkers selected included C-reactive protein (CRP), interleukin-6, tumor necrosis factor-alpha, leptin, adiponectin, ferritin, plasminogen activator inhibitor (PAI)-1, and vascular cell adhesion molecule-1. Data were analyzed using a random-effect model in Review Manager 5.4. Results: Thirty-four studies with 6,261 patients (68.6% male) were eligible for this meta-analysis. The mean age of the participants was 62.57(±11.13) years old, and the median treatment duration length with follow-up was 24 weeks. Generally, the included trials were of good methodological quality. The meta-analysis revealed that ferritin levels were significantly reduced in SGLT2 inhibitor treatment groups versus placebo or standard diabetes therapies (SMD: −1.21; 95% CI: −1.91, −0.52, p < 0.001). The effects of CRP (SMD: 0.25; 95% CI: −0.47, −0.03, p = 0.02) and leptin (SMD: −0.22; 95% CI: −0.43, −0.01, p = 0.04) were reduced, and the effects of adiponectin were improved (SMD: 0.28; 95% CI: 0.15, 0.41, p < 0.001) in placebo-controlled studies. PAI-1 levels were significantly reduced in studies controlled for diabetes therapies (SMD: −0.38; 95% CI: −0.61, −0.15, p = 0.001). Conclusion: This analysis provides strong evidence supporting anti-inflammatory effects of SGLT2 inhibitors in T2D subjects. The mechanisms and possible targets for the inflammation reducing and cardiorenal protective properties of SGLT2 inhibitors remain to be explored. Frontiers Media S.A. 2022-11-11 /pmc/articles/PMC9717685/ /pubmed/36467062 http://dx.doi.org/10.3389/fphar.2022.1045235 Text en Copyright © 2022 Wang, Liu, Zhong, Li, Zhou, Zhang, Li and Xiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Dongmei Liu, Jieying Zhong, Ling Li, Shunhua Zhou, Liyuan Zhang, Qian Li, Ming Xiao, Xinhua The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title | The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title_full | The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title_fullStr | The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title_full_unstemmed | The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title_short | The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials |
title_sort | effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: a systematic review and meta-analysis of randomized controlled trials |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717685/ https://www.ncbi.nlm.nih.gov/pubmed/36467062 http://dx.doi.org/10.3389/fphar.2022.1045235 |
work_keys_str_mv | AT wangdongmei theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT liujieying theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhongling theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT lishunhua theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhouliyuan theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhangqian theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT liming theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaoxinhua theeffectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT wangdongmei effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT liujieying effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhongling effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT lishunhua effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhouliyuan effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhangqian effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT liming effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaoxinhua effectofsodiumglucosecotransporter2inhibitorsonbiomarkersofinflammationasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |